Craft

Medigen Vaccine Biologics

Stock Price

NT$42

2024-10-29

Market Capitalization

NT$13.6 B

2024-10-29

Revenue

NT$605.6 M

FY, 2024

Medigen Vaccine Biologics Summary

Company Summary

Overview
Medigen Vaccine Biologics (高端疫苗生物製劑股份有限公司) is a company developing vaccines and biosimilars to prevent regional infectious diseases. It provides vaccines against enterovirus, pandemic influenza, and dengue virus. The company also offers the Palivizumab biosimilar to prevent respiratory syncytial virus (RSV).
Type
Public
Status
Active
Founded
2012
HQ
TW | view all locations
Website
http://www.medigenvac.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

LocationsView all

1 location detected

  • Taipei City HQ

    Taiwan

    No. 16, Lane 120, Section 1, Zhongshan North Road, Zhongshan District

Medigen Vaccine Biologics Financials

Summary Financials

Revenue (Q3, 2025)
NT$205.9M
Gross profit (Q3, 2025)
NT$116.0M
Net income (Q3, 2025)
(NT$22.6M)
Cash (Q3, 2025)
NT$198.9M
EBIT (Q3, 2025)
(NT$36.0M)
Enterprise value
$13.7B

Footer menu